PDB-code
Browse PDE entries (page 10 of 31)
First 6 7 8 PreviousLast14 13 12 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE1B | 1taz | A | B |  | ||
| Human | PDE1B | 4npv | A | 6,7,8-trimethoxy-N-(pentan-3-yl)quinazolin-4-amine | | ||
| Human | PDE1B | 4npw | A | 7,8-dimethoxy-N-[(2S)-1-(3-methyl-1H-pyrazol-5-yl)propan-2-yl]quinazolin-4-amine | | ||
| Human | PDE1B | 5b25 | A | A | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | A | B | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | B | A | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | B | B | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | C | A | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | C | B | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | D | A | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5b25 | D | B | (11R,15S)-4-{[4-(6-fluoropyridin-2-yl)phenyl]methyl}-8-methyl-5-(phenylamino)-1,3,4,8,10-pentaazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one | | |
| Human | PDE1B | 5uoy | A | 6-[(4-methoxyphenyl)methyl]-9-[(oxan-4-yl)methyl]-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one | | ||
| Human | PDE1B | 5up0 | A | 6-[(4-chlorophenyl)methyl]-8,9,10,11-tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one | | ||
| Human | PDE2A | 1z1l | A | A | | ||
| Human | PDE2A | 1z1l | A | B | | ||
| Human | PDE2A | 3ibj | A | | |||
| Human | PDE2A | 3ibj | B | | |||
| Human | PDE2A | 3itm | A | | |||
| Human | PDE2A | 3itm | B | | |||
| Human | PDE2A | 3itm | C | | |||
| Human | PDE2A | 3itm | D | | |||
| Human | PDE2A | 3itu | A | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE2A | 3itu | B | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE2A | 3itu | C | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE2A | 3itu | D | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE2A | 4c1i | A | (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol | | ||
| Human | PDE2A | 4c1i | B | (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol | | ||
| Human | PDE2A | 4c1i | C | (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol | | ||
| Human | PDE2A | 4c1i | D | (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol | | ||
| Human | PDE2A | 4d08 | A | A | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
